474 related articles for article (PubMed ID: 17401429)
1. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53: an oncogenic transcription factor.
Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
Loging WT; Reisman D
Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of mutant and wild-type p53 on global gene expression.
O'Farrell TJ; Ghosh P; Dobashi N; Sasaki CY; Longo DL
Cancer Res; 2004 Nov; 64(22):8199-207. PubMed ID: 15548685
[TBL] [Abstract][Full Text] [Related]
6. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
7. Interactions of mutant p53 with DNA: guilt by association.
Kim E; Deppert W
Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
[TBL] [Abstract][Full Text] [Related]
8. Targeting gene expression to tumor cells with loss of wild-type p53 function.
Zhu J; Gao B; Zhao J; Balmain A
Cancer Gene Ther; 2000 Jan; 7(1):4-12. PubMed ID: 10678350
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53.
Loging WT; Reisman D
Oncogene; 1999 Dec; 18(52):7608-15. PubMed ID: 10602522
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
13. Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells.
Yan W; Chen X
Cancer Res; 2007 Oct; 67(19):9117-24. PubMed ID: 17909016
[TBL] [Abstract][Full Text] [Related]
14. The role of mutant p53 in human cancer.
Goh AM; Coffill CR; Lane DP
J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
[TBL] [Abstract][Full Text] [Related]
15. Identification of ANKRD11 as a p53 coactivator.
Neilsen PM; Cheney KM; Li CW; Chen JD; Cawrse JE; Schulz RB; Powell JA; Kumar R; Callen DF
J Cell Sci; 2008 Nov; 121(Pt 21):3541-52. PubMed ID: 18840648
[TBL] [Abstract][Full Text] [Related]
16. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
Resnick-Silverman L; Manfredi JJ
J Cell Biochem; 2006 Oct; 99(3):679-89. PubMed ID: 16676359
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
Zalcenstein A; Stambolsky P; Weisz L; Müller M; Wallach D; Goncharov TM; Krammer PH; Rotter V; Oren M
Oncogene; 2003 Aug; 22(36):5667-76. PubMed ID: 12944915
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
19. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the anti-p53 antibody response in cancer patients.
Labrecque S; Naor N; Thomson D; Matlashewski G
Cancer Res; 1993 Aug; 53(15):3468-71. PubMed ID: 8339249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
